Panbela to Host Q2 2024 Earnings Call on Aug 13, 2024

Panbela Therapeutics, Inc., a clinical-stage company based in Minneapolis, is developing groundbreaking treatments for patients with critical unmet medical needs. The company has announced that it will hold a conference call on August 13, 2024, to discuss its second-quarter results for the period ending June 30, 2024.

The call is scheduled for 4:30 PM Eastern Time. Participants can join the call using the following information: the toll-free number is 888-506-0062, and for international callers, the number is 973-528-0011 with the access code 405072. A webcast link is also provided for online access. A replay of the conference call will be available, with details for access provided.

Panbela's therapeutic pipeline is focused on several critical areas, including familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention, and ovarian cancer. The company's development programs are at various stages, from pre-clinical to registration studies, with multiple anticipated catalysts.

Ivospemin (SBP-101) is one of Panbela's leading assets. This proprietary polyamine analogue aims to inhibit polyamine metabolism by targeting pancreatic ductal adenocarcinoma and other tumors. Clinical studies have shown that Ivospemin can inhibit tumor growth in metastatic pancreatic cancer patients, with a median overall survival rate of 14.6 months and an objective response rate of 48%. These results surpass the typical outcomes for the standard chemotherapy regimen of gemcitabine plus nab-paclitaxel. Notably, Ivospemin has not shown increased bone marrow suppression or peripheral neuropathy, common chemotherapy-related adverse effects. However, patients at risk of retinal detachment will be excluded from future studies due to serious visual adverse events observed.

Flynpovi, another significant asset in Panbela's pipeline, is a combination of CPP-1X (eflornithine) and sulindac. This combination uses a dual mechanism to inhibit polyamine synthesis while increasing polyamine export and catabolism. Clinical trials have demonstrated that Flynpovi can prevent over 90% of subsequent pre-cancerous sporadic adenomas compared to placebo. In a recent Phase III trial with FAP patients, those with lower gastrointestinal tract anatomy benefited significantly from Flynpovi compared to single-agent treatments, showing delayed surgical events in the lower GI for up to four years. The safety profile of Flynpovi was comparable to that of the individual agents, supporting its continued evaluation for FAP.

CPP-1X, being developed as a single-agent tablet or high-dose powder sachet, is under investigation for several indications, including gastric cancer prevention, neuroblastoma treatment, and recent-onset Type 1 diabetes. Preclinical studies and early-phase clinical trials suggest CPP-1X is well-tolerated and potentially effective.

Panbela Therapeutics is committed to addressing urgent medical needs through its innovative therapeutic developments. The company’s stock is quoted on the OTCQB market under the symbol “PBLA.” Further information about Panbela can be found on their website.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!